Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study

We evaluated the 3-year drug survival and efficacy of the biosimilar SB4/Benepali in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) patients, previously treated with etanercept (ETA). Drug survival rate was calculated using the Kaplan–Meier method and Cox propor...

Descripción completa

Detalles Bibliográficos
Autores principales: Parisi, Simone, Becciolini, Andrea, Ditto, Maria Chiara, Rozza, Davide, Zanetti, Anna, Laganà, Angela, Peroni, Clara Lisa, Centanaro Di Vittorio, Chiara, Degiovanni, Rosanna, Realmuto, Cristina, Scirè, Carlo Alberto, Priora, Marta, Di Donato, Eleonora, Santilli, Daniele, Mozzani, Flavio, Lucchini, Gianluca, Ariani, Alarico, Gardelli, Lucia, Girelli, Francesco, Arrigoni, Eugenio, Platè, Ilaria, Bravi, Elena, Paroli, Marino, Caccavale, Rosalba, Salvarani, Carlo, Sandri, Gilda, Lumetti, Federica, Volpe, Alessandro, Marchetta, Antonio, Fusaro, Enrico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837069/
https://www.ncbi.nlm.nih.gov/pubmed/35160074
http://dx.doi.org/10.3390/jcm11030621

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837069/
https://www.ncbi.nlm.nih.gov/pubmed/35160074
http://dx.doi.org/10.3390/jcm11030621

Ejemplares similares